[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-tonsillitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-tonsillitis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100637115","recovery-from-tonsil-surgery-100637115",false,"NCT07598201","Recovery From Tonsil Surgery.","Recovery From Tonsil Surgery (FINITE-2). A Randomized, Controlled, Single-blinded Trial Exploring the Recovery and Effectiveness of Two Tonsil Surgery Techniques in Adults.","FINITE-2","Inclusion Criteria:\n\n1. Age 18-65 years\n2. Recurrent or chronic tonsillitis (see above)\n3. Indication for surgical treatment\n4. Eligible for day care surgery\n\nExclusion Criteria:\n\n1. Peritonsillar abscess less than month ago\n2. Previous palatine tonsil surgery (excluding small incision or biopsy)\n3. Current or positive history of a malignant disease\n4. Anticoagulant medication\n5. Contraindication to non-steroidal anti-inflammatory drugs (NSAID) or paracetamol\n6. Other significant co-morbidity\n7. Other contraindications determined by the investigator","ALL","18 Years","65 Years",{"count":21,"type":22},90,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this study is to optimize the duration of sick leave and the usage of opioids following partial tonsillar surgery in adults by comparing the recovery after extracapsular tonsillectomy (ECTE) with recovery after intracapsular tonsillectomy (ICTE). An additional objective is to confirm that ICTE is as effective as ECTE when comparing TOI-14 scores after 12 months post-operatively.\n\nThe main questions the study aims to answer are:\n\n* Is 10 days sick leave enough after partial tonsillectomy (ICTE)?\n* Are opioids needed at all after partial tonsillectomy (ICTE)?\n* Is ICTE as effective as ECTE when comparing TOI-14 symptom scores after 12 months from the surgery?\n\nAdult patients who are scheduled to tonsil surgery are randomised into 2 groups: ICTE and ECTE. Patients are blinded. Postoperatively they will answer structured questions about the recovery and effectiveness of the surgery. The last follow up survey is 60 months after the surgery.",[28,29],"Recurrent Tonsillitis","Chronic Tonsillitis",[31,32],"intracapsular tonsillectomy","extracapsular tonsillectomy","NOT_YET_RECRUITING","2026-05-19",{"date":36,"type":37},"2026-05-20","ACTUAL",{"date":39,"type":22},"2026-06-01",{"date":41,"type":22},"2030-12",{"name":43,"class":44},"Turku University Hospital","OTHER_GOV",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100611072","evaluation-of-the-efficacy-of-streptococcus-salivarius-evol12-in-the-reduction-of-recurrent-adenotonsillitis-in-children-100611072","NCT07235826","Evaluation of the Efficacy of Streptococcus Salivarius Evol12® in the Reduction of Recurrent Adenotonsillitis in Children","Evaluation of the Efficacy of Streptococcus Salivarius Evol12® in the Reduction of Recurrent Adenotonsillitis in Children: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Cross-over Clinical Trial","Inclusion Criteria:\n\n* Male and female children aged 3 to 11 years.\n* History of ≥3 documented episodes of acute adenotonsillitis within the previous 12 months, each characterized by fever ≥38°C.\n* Signed and accepted informed consent from a parent or legal guardian.\n\nExclusion Criteria:\n\n* Total obstruction of the nasal cavities.\n* Uncontrolled gastroesophageal reflux disease.\n* Unilateral tonsillar enlargement.\n* Previous tonsil reduction surgery.\n* Lack of parental or legal guardian consent to participate in the study.","3 Years","11 Years",{"count":55,"type":22},200,[25],"This prospective, multicenter, randomized, double-blind, placebo-controlled, cross-over clinical trial will evaluate the efficacy and safety of Streptococcus salivarius Evol12® (Bactoblis® Evol) in reducing the recurrence and duration of acute febrile adenotonsillitis in children aged 3 to 11 years. Participants will receive either the probiotic or a matching placebo for 3 months, followed by a 7-day wash-out and a second 3-month treatment period with the alternative product. The study will assess changes in the incidence and duration of adenotonsillar episodes, antibiotic use, school absences, and sleep quality.",[28],"RECRUITING","2025-11-17",{"date":62,"type":37},"2025-11-19",{"date":64,"type":37},"2025-09-01",{"date":66,"type":22},"2026-06-30",{"name":68,"class":69},"Liaquat University of Medical & Health Sciences","OTHER",1]